 |
|
|
| |
RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Adults
With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection With Severe Renal Impairment or End-Stage Renal Disease
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
John M Vierling1, Eric Lawitz2, K Rajender Reddy3, Eric Cohen4, Nyingi Kemmer5, Giuseppe Morelli6, Philippe J Zamor7, Michael Bennett 8, David Bernstein9, Kris Kowdley10, Parvez S Mantry11,
Paul J Pockros12, David Wyles13, Sonal Kumar14, Kalyan Ram Bhamidimarri15, Daniel E Cohen4, Tami Pilot-Mati as4, Zhenzhen Zhang4, Thomas Podsadecki4, Tarek Hassanein16
1Baylor College of Medicine; Advanced Liver Therapies, Houston, Texas, United States; 2The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States; 3University of Pennsylvania, Philadelphia, Pennsylvania, United States; 4AbbVie Inc., North Chicago, Illinois, United States;
5Tampa General Medical Group, Tampa, Florida, United States; 6University of Florida Health Science Center, Gainesville, Florida, United States; 7Carolinas Medical Center, Charlotte, North Carolina, United States; 8Medical Associates Research Group, San Diego, California, United States;
9North Shore University Hospital, Manhasset, New York, United States; 10Swedish Medical Center, Seatt le, Washington, United States; 11The Liver Institute at Methodist Dallas, Dallas, Texas, United States; 12Scripps Clinic, San Diego, California, United States;
13University of California San Diego, La Jolla, California, United States; 14Weill Cornell Medical College, New York, New York, United States; 15University of Miami, Miami, Florida, United States; 16Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States
|
| |
|
|
|
|
|
